Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Income towards Parent Company (2022 - 2026)

Axsome Therapeutics' Income towards Parent Company history spans 5 years, with the latest figure at -$64.5 million for Q1 2026.

  • On a quarterly basis, Income towards Parent Company fell 8.63% to -$64.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$188.3 million, a 32.33% increase, with the full-year FY2025 number at -$183.2 million, up 36.21% from a year prior.
  • Income towards Parent Company hit -$64.5 million in Q1 2026 for Axsome Therapeutics, down from -$28.6 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for AXSM hit a ceiling of -$11.2 million in Q1 2023 and a floor of -$98.7 million in Q4 2023.
  • Historically, Income towards Parent Company has averaged -$56.5 million across 5 years, with a median of -$61.2 million in 2022.
  • Biggest five-year swings in Income towards Parent Company: skyrocketed 71.64% in 2023 and later tumbled 508.27% in 2024.
  • Tracing AXSM's Income towards Parent Company over 5 years: stood at -$61.2 million in 2022, then tumbled by 61.09% to -$98.7 million in 2023, then grew by 24.06% to -$74.9 million in 2024, then soared by 61.84% to -$28.6 million in 2025, then crashed by 125.76% to -$64.5 million in 2026.
  • Business Quant data shows Income towards Parent Company for AXSM at -$64.5 million in Q1 2026, -$28.6 million in Q4 2025, and -$47.2 million in Q3 2025.